KRYS (Krystal Corp) Margin operasi

Logo perusahaan publik Krystal Biotech Corp. (KRYS)

Krystal Biotech, Inc. (KRYS) automates the production of gene therapies via bioreactors while maintaining sterility. A neutral geopolitical status ensures stable global distribution. The operating profit margin visualizes these successes, where the 48.40 metric determines the profitability parameter status. Ultimately, the unique gene delivery system establishes a new standard for treating rare dermatological pathologies.

Krystal Biotech Inc (KRYS): Rentabilitas operasi saka 04.07.2022 nganti 19.11.2026

Rincian metrik komprehensif lan analitis Krystal Biotech, Inc. (KRYS)

Analisis wiwitan perusahaan:KRYS, krystalbio.com
Produk dadi Krystal Biotech Corp.

To assess the credit quality of Krystal Biotech, Inc. (KRYS), the analyst examines the operating margin—the ratio of operating income before interest and taxes to revenue—which determines cost management efficiency. The trend in the operating margin reflects the company's ability to monetize breakthrough gene therapy developments and scale its R&D pipeline, converting scientific innovations into a sustainable cash flow.